The chromosome 21 kinase DYRK1A: emerging roles in cancer biology and potential as a therapeutic target

Cancer stem cells revisited

Batlle, E., & Clevers, H. (2017) · Nature Medicine · doi:10.1038/nm.4409 · Cited by 2,769 · see citing works

Stat3: a STAT Family Member Activated by Tyrosine Phosphorylation in Response to Epidermal Growth Factor and Interleukin-6

Zhong, Z., Wen, Z., & Darnell, J. E. (1994) · Science · doi:10.1126/science.8140422 · Cited by 2,070 · see citing works

Maximal activation of transcription by statl and stat3 requires both tyrosine and serine phosphorylation

Wen, Z., Zhong, Z., & Darnell, J. E. (1995) · Cell · doi:10.1016/0092-8674(95)90311-9 · Cited by 1,974 · see citing works

NFAT proteins: key regulators of T-cell development and function

Macián, F. (2005) · Nature reviews. Immunology · doi:10.1038/nri1632 · Cited by 1,575 · see citing works

Lamellarins and Related Pyrrole-Derived Alkaloids from Marine Organisms

Fan, H., Peng, J., Hamann, M. T., et al. (2007) · Chemical Reviews · doi:10.1021/cr078199m · Cited by 1,060 · see citing works

NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21

Arron, J. R., Winslow, M. M., Polleri, A., Chang, C.-P., Wu, H., Gao, X., Neilson, J. R., Chen, L., Heit, J. J., Kim, S. K., et al. (2006) · Nature · doi:10.1038/nature04678 · Cited by 698 · see citing works

Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors

Siveen, K. S., Sikka, S., Surana, R., Dai, X., Zhang, J., Kumar, A. P., Tan, B. K. H., Sethi, G., & Bishayee, A. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.12.005 · Cited by 637 · see citing works

Phase-separation mechanism for C-terminal hyperphosphorylation of RNA polymerase II

Lu, H., Yu, D., Hansen, A. S., Ganguly, S., Liu, R., Heckert, A. B., Darzacq, X., & Zhou, Q. (2018) · Nature · doi:10.1038/s41586-018-0174-3 · Cited by 576 · see citing works

CX-4945, an Orally Bioavailable Selective Inhibitor of Protein Kinase CK2, Inhibits Prosurvival and Angiogenic Signaling and Exhibits Antitumor Efficacy

Siddiqui-Jain, A., Drygin, D., Streiner, N., Chua, P. C., Pierre, F., O’Brien, S., Bliesath, J., Omori, M., Huser, N. H., Ho, C., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1893 · Cited by 511 · see citing works

Alternative splicing and cancer: a systematic review

Zhang, Y., Qian, J., Gu, C., & Yang, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00486-7 · Cited by 503 · see citing works

Ubiquitin ligases in oncogenic transformation and cancer therapy

Senft, D., Qi, J., & Ronai, Z. A. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.105 · Cited by 490 · see citing works

Molecular Mapping of Twenty-Four Features of Down Syndrome on Chromosome 21

Delabar, J. M., Theophile, D., Rahmani, Z., Chettouh, Z., Blouin, J., Prieur, M., Noel, B., & Sinet, P. (1993) · European Journal of Human Genetics · doi:10.1159/000472398 · Cited by 454 · see citing works

The role of NFAT transcription factors in integrin-mediated carcinoma invasion

Jauliac, S., López‐Rodríguez, C., Shaw, L. M., Brown, L. F., Rao, A., & Toker, A. (2002) · Nature Cell Biology · doi:10.1038/ncb816 · Cited by 409 · see citing works

STAT3 SIGNALING: Anticancer Strategies and Challenges

Johnston, P. A., & Grandis, J. R. (2011) · Molecular Interventions · doi:10.1124/mi.11.1.4 · Cited by 407 · see citing works

Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome

Altafaj, X. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.18.1915 · Cited by 396 · see citing works

EGF Receptor Signaling Is Essential for K-Ras Oncogene-Driven Pancreatic Ductal Adenocarcinoma

Navas, C., Hernández-Porras, I., Schuhmacher, A. J., Sibilia, M., Guerra, C., & Barbacid, M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.001 · Cited by 391 · cited 5× · see citing works

minibrain: A new protein kinase family involved in postembryonic neurogenesis in Drosophila

Tejedor, F. J., Zhu, X., Kaltenbach, E., Ackermann, A., Baumann, A., Canal, I., Heisenberg, M., Fischbach, K. F., & Pongs, O. (1995) · Neuron · doi:10.1016/0896-6273(95)90286-4 · Cited by 379 · see citing works

Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1

Baek, K., Zaslavsky, A., Lynch, R. C., Britt, C., Okada, Y., Siarey, R. J., Lensch, M. W., Park, I., Yoon, S. S., Minami, T., et al. (2009) · Nature · doi:10.1038/nature08062 · Cited by 374 · see citing works

Potential Therapeutic Targets of Epigallocatechin Gallate (EGCG), the Most Abundant Catechin in Green Tea, and Its Role in the Therapy of Various Types of Cancer

Almatroodi, S. A., Almatroudi, A., Khan, A. A., Alhumaydhi, F. A., Alsahli, M. A., & Rahmani, A. H. (2020) · Molecules · doi:10.3390/molecules25143146 · Cited by 366 · see citing works

DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assembly

Litovchick, L., Florens, L. A., Swanson, S. K., Washburn, M. P., & DeCaprio, J. A. (2011) · Genes & Development · doi:10.1101/gad.2034211 · Cited by 302 · see citing works

FOXO transcription factor family in cancer and metastasis

Jiramongkol, Y., & Lam, E. W. ‐. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09883-w · Cited by 285 · see citing works

SCFβ-TRCP controls oncogenic transformation and neural differentiation through REST degradation

Westbrook, T. F., Hu, G., Ang, X. L., Mulligan, P., Pavlova, N. N., Liang, A., Leng, Y., Maehr, R., Shi, Y., Harper, J. W., et al. (2008) · Nature · doi:10.1038/nature06780 · Cited by 275 · see citing works

FOXO Forkhead Transcription Factors Induce G2-M Checkpoint in Response to Oxidative Stress

Furukawa‐Hibi, Y., Yoshida-Araki, K., Ohta, T., Ikeda, K., & Motoyama, N. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200256200 · Cited by 271 · see citing works

The kinase DYRK1A phosphorylates the transcription factor FKHR at Ser329 in vitro, a novel in vivo phosphorylation site

Woods, Y. L., Rena, G., MORRICE, N. A., Barthel, A., Becker, W. B., Guo, S., Unterman, T. G., & Cohen, P. (2001) · Biochemical Journal · doi:10.1042/bj3550597 · Cited by 265 · see citing works

Dyrk, a Dual Specificity Protein Kinase with Unique Structural Features Whose Activity Is Dependent on Tyrosine Residues between Subdomains VII and VIII

Kentrup, H., Becker, W. B., Heukelbach, J., Wilmes, A., Schürmann, A., Huppertz, C., Kainulainen, H., & Joost, H. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.7.3488 · Cited by 259 · see citing works

Inhibition of Monoamine Oxidase A by β-Carboline Derivatives

Kim, H., Sablin, S. O., & Ramsay, R. R. (1997) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1996.9771 · Cited by 252 · see citing works

DYRK1A and DYRK3 Promote Cell Survival through Phosphorylation and Activation of SIRT1

Guo, X., Williams, J. G., Schug, T. T., & Li, X. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.102574 · Cited by 237 · see citing works

Requirement of MEF2A, C, and D for skeletal muscle regeneration

Liu, N., Nelson, B. R., Bezprozvannaya, S., Shelton, J. M., Richardson, J. A., Bassel‐Duby, R., & Olson, E. N. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1401732111 · Cited by 227 · see citing works

Structural and Functional Characteristics of Dyrk, a Novel Subfamily of Protein Kinases with Dual Specificity

Becker, W. B., & Joost, H. (1998) · Progress in nucleic acid research and molecular biology · doi:10.1016/s0079-6603(08)60503-6 · Cited by 226 · see citing works

FGF-2 Regulates Cell Proliferation, Migration, and Angiogenesis through an NDY1/KDM2B-miR-101-EZH2 Pathway

Kottakis, F., Polytarchou, C., Foltopoulou, P. F., Sanidas, I., Kampranis, S. C., & Tsichlis, P. N. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.06.020 · Cited by 224 · see citing works

Identification of the autophosphorylation sites and characterization of their effects in the protein kinase DYRK1A

Himpel, S., PANZER, P., EIRMBTER, K., Czajkowska, H., Sayed, M., Packman, L. C., Blundell, T. L., Kentrup, H., Grötzinger, J., Joost, H., et al. (2001) · Biochemical Journal · doi:10.1042/bj3590497 · Cited by 209 · see citing works

Polyaromatic alkaloids from marine invertebrates as cytotoxic compounds and inhibitors of multidrug resistance caused by P-glycoprotein

Quesada, A. R., Gravalos, G. M. D., & Puentes, J. F. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.421 · Cited by 195 · see citing works

The Down syndrome-related protein kinase DYRK1A phosphorylates p27^Kip1and Cyclin D1 and induces cell cycle exit and neuronal differentiation

Soppa, U., Schumacher, J., Florencio Ortiz, V., Pasqualon, T., Tejedor, F., & Becker, W. (2014) · Cell Cycle · doi:10.4161/cc.29104 · Cited by 189 · see citing works

Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome

Malinge, S., Bliss‐Moreau, M., Kirsammer, G. T., Diebold, L. P., Chlon, T. M., Gurbuxani, S. K., & Crispino, J. D. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60455 · Cited by 180 · see citing works

Increased Dosage of Dyrk1A Alters Alternative Splicing Factor (ASF)-regulated Alternative Splicing of Tau in Down Syndrome

Shi, J., Zhang, T., Zhou, C., Chohan, M. O., Gu, X., Węgiel, J., Zhou, J., Hwang, Y., Iqbal, K., Grundke, I., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802645200 · Cited by 179 · see citing works

Isolation of Human and Murine Homologues of theDrosophilaMinibrain Gene: Human Homologue Maps to 21q22.2 in the Down Syndrome “Critical Region”

Song, W., Sternberg, L. R., Kasten-Sportès, C., Keuren, M. L. V., Chung, S.-H., Slack, A. C., Miller, D. E., Glover, T. W., Chiang, P.-W., Lou, L., et al. (1996) · Genomics · doi:10.1006/geno.1996.0636 · Cited by 177 · see citing works

DYRK1A accumulates in splicing speckles through a novel targeting signal and induces speckle disassembly

Álvarez‐Fernández, M., Estivill, X., & de la Luna, S. (2003) · Journal of Cell Science · doi:10.1242/jcs.00618 · Cited by 161 · see citing works

Structures of Down Syndrome Kinases, DYRKs, Reveal Mechanisms of Kinase Activation and Substrate Recognition

Soundararajan, M., Roos, A. K., Savitsky, P. A., Filippakopoulos, P., Kettenbach, A. N., Olsen, J. V., Gerber, S. A., Eswaran, J., Knapp, S., & Elkins, J. M. (2013) · Structure · doi:10.1016/j.str.2013.03.012 · Cited by 160 · see citing works

DYRK1A-Dosage Imbalance Perturbs NRSF/REST Levels, Deregulating Pluripotency and Embryonic Stem Cell Fate in Down Syndrome

Canzonetta, C., Mulligan, C., Deutsch, S., Ruf, S., O’Doherty, A., Lyle, R., Borel, C., Lin-Marq, N., Delom, F., Groet, J., et al. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.08.012 · Cited by 158 · see citing works

Prognostic role of STAT3 in solid tumors: a systematic review and meta-analysis

Wu, P., Wu, D., Zhao, L., Huang, L., Shen, G., Huang, J., & Chai, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.7887 · Cited by 148 · see citing works

DYRK1A haploinsufficiency causes a new recognizable syndrome with microcephaly, intellectual disability, speech impairment, and distinct facies

Ji, J., Lee, H., Argiropoulos, B., Dorrani, N., Mann, J., Martinez-Agosto, J. A., Gomez-Ospina, N., Gallant, N., Bernstein, J. A., Hudgins, L., et al. (2015) · European Journal of Human Genetics · doi:10.1038/ejhg.2015.71 · Cited by 145 · see citing works

Dosage of Dyrk1a shifts cells within a p21-cyclin D1 signaling map to control the decision to enter the cell cycle

Chen, J.-Y., Lin, J.-R., Tsai, F.-C., & Meyer, T. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.09.009 · Cited by 144 · see citing works

Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth

Pozo, N., Zahonero, C., Fernández, P., Liñares, J. M., Ayuso‐Sacido, Á., Hagiwara, M., Pérez‐Núñez, Á., Ricoy, J. R., Hernández‐Laín, A., Sepúlveda-Sánchez, J. M., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci63623 · Cited by 142 · see citing works

DYRK1A interacts with the REST/NRSF-SWI/SNF chromatin remodelling complex to deregulate gene clusters involved in the neuronal phenotypic traits of Down syndrome

Lepagnol-Bestel, A.-M., Zvara, Á., Maussion, G., Quignon, F., Ngimbous, B., Ramoz, N., Imbeaud, S., Loe-Mie, Y., Benihoud, K., Agier, N., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp047 · Cited by 137 · see citing works

Natural Polyphenols that Display Anticancer Properties through Inhibition of Kinase Activity

Lamoral-Theys, D., Pottier, L. R., Dufrasne, F., et al. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710790712183 · Cited by 136 · see citing works

Dyrk1A phosphorylates p53 and inhibits proliferation of embryonic neuronal cells

Park, J., Oh, Y., Yoo, L., Jung, M.-S., Song, W.-J., Lee, S.-H., Seo, H., & Chung, K. C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.147520 · Cited by 134 · see citing works

Myocyte Enhancer Factor 2A and 2D Undergo Phosphorylation and Caspase-Mediated Degradation during Apoptosis of Rat Cerebellar Granule Neurons

Li, M., Linseman, D. A., Allen, M. P., Meintzer, M. K., Wang, X., Laessig, T. A., Wierman, M. E., & Heidenreich, K. A. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-17-06544.2001 · Cited by 130 · see citing works

Chromatin-wide Profiling of DYRK1A Reveals a Role as a Gene-Specific RNA Polymerase II CTD Kinase

Vona, C. D., Bezdan, D., Islam, A. B. M. M. K., Salichs, E., López-Bigas, N., Ossowski, S., & de la Luna, S. (2015) · Molecular Cell · doi:10.1016/j.molcel.2014.12.026 · Cited by 129 · see citing works

An ID2-dependent mechanism for VHL inactivation in cancer

Lee, S. B., Frattini, V., Bansal, M., Castano, A. M., Sherman, D., Hutchinson, K., Bruce, J. N., Califano, A., Liu, G., Cardozo, T. J., et al. (2016) · Nature · doi:10.1038/nature16475 · Cited by 127 · see citing works

Pharmacological effects of harmine and its derivatives: a review

Zhang, L., Li, D.-C., & Yu, S. (2020) · Archives of Pharmacal Research · doi:10.1007/s12272-020-01283-6 · Cited by 122 · see citing works

A novel DYRK1A (Dual specificity tyrosine phosphorylation‐regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro

Coutadeur, S., Benyamine, H., Delalonde, L., de Oliveira, C., Leblond, B., Foucourt, A., Besson, T., Casagrande, A.-S., Taverne, T., Girard, A., et al. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.13018 · Cited by 121 · see citing works

The calcineurin/NFAT pathway is activated in diagnostic breast cancer cases and is essential to survival and metastasis of mammary cancer cells

Quang, C. T., Leboucher, S., Passaro, D., et al. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.14 · Cited by 115 · see citing works

Forced expression of a constitutively active form of Stat3 in mouse epidermis enhances malignant progression of skin tumors induced by two-stage carcinogenesis

Chan, K., Sano, S., Kataoka, K., Abel, E. L., Carbajal, S., Beltrán, L. M., Clifford, J., Peavey, M., Shen, J., & DiGiovanni, J. (2008) · Oncogene · doi:10.1038/sj.onc.1210726 · Cited by 113 · see citing works

The protein kinase DYRK1A phosphorylates the splicing factor SF3b1/SAP155 at Thr434, a novel in vivo phosphorylation site

de Graaf, K., Czajkowska, H., Rottmann, S., Packman, L. C., Lilischkis, R., Lüscher, B., & Becker, W. B. (2006) · BMC Biochemistry · doi:10.1186/1471-2091-7-7 · Cited by 109 · see citing works

REST Regulates Oncogenic Properties of Glioblastoma Stem Cells

Kamal, M. M., Sathyan, P., Singh, S. K., Zinn, P. O., Marisetty, A., Liang, S., Gumin, J., EL-Mesallamy, H. O., Suki, D., Colman, H., et al. (2012) · Stem Cells · doi:10.1002/stem.1020 · Cited by 108 · see citing works

Green tea extracts for the prevention of metachronous colorectal polyps among patients who underwent endoscopic removal of colorectal adenomas: A randomized clinical trial

Shin, C. M., Lee, D. H., Seo, A. Y., Lee, H. J., Kim, S. B., Son, W., Kim, Y. K., Lee, S. J., Park, S.-H., Kim, N., et al. (2017) · Clinical Nutrition · doi:10.1016/j.clnu.2017.01.014 · Cited by 107 · see citing works

Simultaneous Tyrosine and Serine Phosphorylation of STAT3 Transcription Factor Is Involved in Rho A GTPase Oncogenic Transformation

Benitah, S. A., Valerón, P. F., Rincon, S. V. D., Fernández‐Pérez, L., Perona, R., & Lacal, J. C. (2001) · Molecular Biology of the Cell · doi:10.1091/mbc.12.10.3282 · Cited by 103 · see citing works

Role and Regulation of STAT3 Phosphorylation at Ser727 in Melanocytes and Melanoma Cells

Sakaguchi, M., Oka, M., Iwasaki, T., Fukami, Y., & Nishigori, C. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.45 · Cited by 100 · see citing works

Regulation of the alternative splicing of tau exon 10 by SC35 and Dyrk1A

Wu, Q., Liang, H., Shi, J., Jin, N., Grundke, I., Iqbal, K., Gong, C., & Liu, F. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr195 · Cited by 100 · see citing works

Link Between DYRK1A Overexpression and Several-Fold Enhancement of Neurofibrillary Degeneration With 3-Repeat Tau Protein in Down Syndrome

Węgiel, J., Kaczmarski, W., Barua, M., Kuchna, I., Nowicki, K., Wang, K.-C., Wegiel, J., Mazur‐Kolecka, B., Frackowiak, J., Mazur‐Kolecka, B., et al. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318202bfa1 · Cited by 98 · see citing works

DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth

Luna, J., Boni, J., Cuatrecasas, M., Ros, X. B., Núñez-Manchón, E., Gironella, M., Vaquero, E. C., Arbonés, M. L., de la Luna, S., & Fillat, C. (2018) · Gut · doi:10.1136/gutjnl-2018-316128 · Cited by 94 · see citing works

Dual-specificity Tyrosine Phosphorylation-regulated Kinase 1A (Dyrk1A) Modulates Serine/Arginine-rich Protein 55 (SRp55)-promoted Tau Exon 10 Inclusion

Yin, X., Jin, N., Gu, J., Shi, J., Zhou, J., Gong, C., Iqbal, K., Grundke, I., & Liu, F. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.355412 · Cited by 93 · see citing works

Proinflammatory TLR signalling is regulated by a TRAF2-dependent proteolysis mechanism in macrophages

Jin, J., Xiao, Y., Hu, H., et al. (2015) · Nature Communications · doi:10.1038/ncomms6930 · Cited by 93 · see citing works

DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3

Bhansali, R. S., Rammohan, M., Lee, P., Laurent, A. P., Wen, Q., Suraneni, P. K., Yip, B. H., Tsai, Y.-C., Jenni, S., Bornhauser, B. C., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci135937 · Cited by 92 · see citing works

REST: an oncogene or a tumor suppressor?

Negrini, S., Prada, I., D’Alessandro, R., & Meldolesi, J. (2013) · Trends in Cell Biology · doi:10.1016/j.tcb.2013.01.006 · Cited by 83 · see citing works

DYRK1A controls the transition from proliferation to quiescence during lymphoid development by destabilizing Cyclin D3

Thompson, B. J., Bhansali, R. S., Diebold, L. P., Cook, D. E., Stolzenburg, L. R., Casagrande, A.-S., Besson, T., Leblond, B., Désiré, L., Malinge, S., et al. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20150002 · Cited by 83 · see citing works

NOTCH3 expression is linked to breast cancer seeding and distant metastasis

Leontovich, A. A., Jalalirad, M., Salisbury, J. L., Mills, L., Haddox, C. L., Schroeder, M. A., Tuma, A. C. M., Guicciardi, M. E., Zammataro, L. A., Gambino, M. W., et al. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-1020-0 · Cited by 82 · see citing works

Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling

Buontempo, F., Orsini, E., Martins, L. R., Antunes, I., Lonetti, A., Chiarini, F., Tabellini, G., Evangelisti, C., Evangelisti, C., Melchionda, F., et al. (2013) · Leukemia · doi:10.1038/leu.2013.349 · Cited by 80 · see citing works

Regulated Segregation of Kinase Dyrk1A during Asymmetric Neural Stem Cell Division Is Critical for EGFR-Mediated Biased Signaling

Ferrón, S. R., Pozo, N., Laguna, A., Aranda, S., Porlan, E., Moreno‐Estellés, M., Fillat, C., de la Luna, S., Sánchez‐Gómez, P., Arbonés, M. L., et al. (2010) · Cell stem cell · doi:10.1016/j.stem.2010.06.021 · Cited by 79 · see citing works

Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Aβ25–35 peptide administration in mice

Naert, G., Ferré, V. M., Meunier, J., Keller, E., Malmström, S., Givalois, L., Carreaux, F., Bazureau, J. P., & Maurice, T. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.03.018 · Cited by 75 · see citing works

The MNB/DYRK1A protein kinase: Genetic and biochemical properties

Galcerán, J., de Graaf, K., Tejedor, F. J., & Becker, W. B. (2003) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6721-2_12 · Cited by 74 · see citing works

ATM Augments Nuclear Stabilization of DYRK2 by Inhibiting MDM2 in the Apoptotic Response to DNA Damage

Taira, N., Yamamoto, H., Yamaguchi, T., Miki, Y., & Yoshida, K. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.042341 · Cited by 73 · see citing works

Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia

Martins, L. R., Lúcio, P., Melão, A., et al. (2013) · Leukemia · doi:10.1038/leu.2013.232 · Cited by 72 · see citing works

Tumor Suppressor DYRK1A Effects on Proliferation and Chemoresistance of AML Cells by Downregulating c-Myc

Liu, Q., Liu, N., Zang, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098853 · Cited by 71 · see citing works

Alkaloids from Marine Invertebrates as Important Leads for Anticancer Drugs Discovery and Development

Imperatore, C., Aiello, A., D'Aniello, F., et al. (2014) · Molecules · doi:10.3390/molecules191220391 · Cited by 71 · see citing works

Truncation and Activation of Dual Specificity Tyrosine Phosphorylation-regulated Kinase 1A by Calpain I

Jin, N., Yin, X., Gu, J., Zhang, X., Shi, J., Qian, W., Ji, Y., Cao, M., Gu, X., Ding, F., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.645507 · Cited by 71 · see citing works

A wake‐up call to quiescent cancer cells – potential use of DYRK 1B inhibitors in cancer therapy

Becker, W. B. (2017) · FEBS Journal · doi:10.1111/febs.14347 · Cited by 71 · see citing works

DYRK1A Protein, A Promising Therapeutic Target to Improve Cognitive Deficits in Down Syndrome

Féki, A., & Hibaoui, Y. (2018) · Brain Sciences · doi:10.3390/brainsci8100187 · Cited by 71 · see citing works

RNF169 limits 53BP1 deposition at DSBs to stimulate single-strand annealing repair

An, L., Dong, C., Li, J., Chen, J., Yuan, J., Huang, J., Chan, K. M., Yu, C., & Huen, M. S. Y. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1804823115 · Cited by 69 · see citing works

A Systematic Analysis of Negative Growth Control Implicates the DREAM Complex in Cancer Cell Dormancy

MacDonald, J. I., Ramos-Valdes, Y., Perampalam, P., Litovchick, L., DiMattia, G. E., & Dick, F. A. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0323-t · Cited by 67 · see citing works

Selectivity Profiling and Biological Activity of Novel β-Carbolines as Potent and Selective DYRK1 Kinase Inhibitors

Rüben, K., Wurzlbauer, A., Walte, A., Sippl, W., Bracher, F., & Becker, W. B. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132453 · Cited by 65 · see citing works

Regulation of alternative splicing of tau exon 10 by 9G8 and Dyrk1A

Ding, S., Shi, J., Qian, W., Iqbal, K., Grundke, I., Gong, C., & Liu, F. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.11.021 · Cited by 60 · see citing works

DYRK1A binds to an evolutionarily conserved WD40-repeat protein WDR68 and induces its nuclear translocation

Miyata, Y., & Nishida, E. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.06.023 · Cited by 60 · see citing works

DYRK1A overexpression enhances STAT activity and astrogliogenesis in a Down syndrome mouse model

Kurabayashi, N., Nguyen, M. D., & Sanada, K. (2015) · EMBO Reports · doi:10.15252/embr.201540374 · Cited by 57 · see citing works

DYRK1A Kinase Positively Regulates Angiogenic Responses in Endothelial Cells

Rozen, E. J., Roewenstrunk, J., Barallobre, M. J., Vona, C. D., Jung, C., Figueiredo, A. M., Luna, J., Fillat, C., Arbonés, M. L., Graupera, M., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.04.008 · Cited by 57 · see citing works

Splice Variants of the Dual Specificity Tyrosine Phosphorylation-regulated Kinase 4 (DYRK4) Differ in Their Subcellular Localization and Catalytic Activity*

Papadopoulos, C., Arató, K., Lilienthal, E., Zerweck, J., Schutkowski, M., Chatain, N., Müller-Newen, G., Becker, W., & de la Luna, S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.157909 · Cited by 56 · see citing works

Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity

Tubi, L. Q., Gurrieri, C., Brancalion, A., Bonaldi, L., Bertorelle, R., Manni, S., Pavan, L., Lessi, F., Zambello, R., Trentin, L., et al. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-78 · Cited by 56 · see citing works

Active Stat3 is required for survival of human squamous cell carcinoma cells in serum-free conditions

Yin, W., Cheepala, S., Roberts, J. N., Chan, K. S., DiGiovanni, J., & Clifford, J. L. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-15 · Cited by 56 · see citing works

DYRK1a mediates BAFF-induced noncanonical NF-κB activation to promote autoimmunity and B-cell leukemogenesis

Li, Y., Xie, X., Jie, Z., et al. (2021) · Blood · doi:10.1182/blood.2021011247 · Cited by 56 · see citing works

The nuclear interactome of DYRK1A reveals a functional role in DNA damage repair

Guard, S., Poss, Z., Ebmeier, C., Pagratis, M., Simpson, H., Taatjes, D., & Old, W. (2018) · Scientific Reports · doi:10.1038/s41598-019-42990-5 · Cited by 54 · see citing works

CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway

Prins, R. C., Burke, R. T., Tyner, J. W., et al. (2013) · Leukemia · doi:10.1038/leu.2013.228 · Cited by 53 · see citing works

DYRK1A regulates the recruitment of 53BP1 to the sites of DNA damage in part through interaction with RNF169

Menon, V., Ananthapadmanabhan, V., Swanson, S. K., Saini, S., Sesay, F. F., Yakovlev, V. A., Florens, L. A., DeCaprio, J. A., Washburn, M. P., Dozmorov, M. G., et al. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1577525 · Cited by 53 · see citing works

DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild‐type NSCLC cells to AZD9291

Li, Y.-L., Ding, K., Hu, X., Wu, L., Zhou, D., Rao, M., Lin, N., & Zhang, C. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14609 · Cited by 53 · see citing works

A dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma

Radhakrishnan, A., Nanjappa, V., Raja, R., Sathe, G. J., Puttamallesh, V. N., Jain, A., Pinto, S. M., Andugulapati, S. B., Chavan, S., Sahasrabuddhe, N. A., et al. (2016) · Scientific Reports · doi:10.1038/srep36132 · Cited by 52 · see citing works

Global phosphoproteomics reveals DYRK1A regulates CDK1 activity in glioblastoma cells

Recasens, A., Humphrey, S. J., Ellis, M., Hoque, M., Abbassi, R. H., Chen, B., Longworth, M., Needham, E. J., James, D. E., Johns, T. G., et al. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00456-6 · Cited by 52 · see citing works

Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: Development of chemical probe ML315

Coombs, T. C., Tanega, C., Shen, M., Wang, J. L., Auld, D. S., Gerritz, S. W., Schoenen, F. J., Thomas, C. J., & Aubé, J. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.02.096 · Cited by 51 · see citing works

Characterization of a Domain That Transiently Converts Class 2 DYRKs into Intramolecular Tyrosine Kinases

Kinstrie, R., Luebbering, N., Miranda‐Saavedra, D., Sibbet, G. J., Han, J., Lochhead, P. A., & Cleghon, V. (2010) · Science Signaling · doi:10.1126/scisignal.2000579 · Cited by 50 · see citing works

A comprehensive proteomics-based interaction screen that links DYRK1A to RNF169 and to the DNA damage response

Roewenstrunk, J., Vona, C. D., Chen, J., Borràs, E., Dong, C., Arató, K., Sabidó, E., Huen, M. S. Y., & de la Luna, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-42445-x · Cited by 48 · see citing works

Fragment-Derived Selective Inhibitors of Dual-Specificity Kinases DYRK1A and DYRK1B

Walmsley, L., Murray, J. B., Dokurno, P., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00024 · Cited by 44 · see citing works

New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis

Tazarki, H., Zeinyeh, W., Esvan, Y. J., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.01.052 · Cited by 41 · see citing works

A complex between DYRK1A and DCAF7 phosphorylates the C-terminal domain of RNA polymerase II to promote myogenesis

Yu, D., Cattoglio, C., Xue, Y., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz162 · Cited by 41 · see citing works

REST Regulates DYRK1A Transcription in a Negative Feedback Loop

Lü, M., Zheng, L., Han, B., Wang, L., Wang, P., Liu, H., & Sun, X. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.174540 · Cited by 39 · see citing works

Inhibition of DYRK1A-EGFR axis by p53-MDM2 cascade mediates the induction of cellular senescence

Xu, X., Liu, Q., Zhang, C., Ren, S., Xu, L., Zhao, Z., Dou, H., Li, P., Zhang, X., Gong, Y., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1521-5 · Cited by 39 · see citing works

Structure-Guided Discovery of Potent and Selective DYRK1A Inhibitors

Weber, C., Sipos, M., Paczal, A., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00023 · Cited by 37 · see citing works

Structure‐Based Design and Synthesis of Harmine Derivatives with Different Selectivity Profiles in Kinase versus Monoamine Oxidase Inhibition

Bálint, B., Weber, C., Cruzalegui, F. H., et al. (2017) · ChemMedChem · doi:10.1002/cmdc.201600539 · Cited by 36 · see citing works

MuvB: A Key to Cell Cycle Control in Ovarian Cancer

Iness, A. N., & Litovchick, L. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00223 · Cited by 34 · see citing works

Impact of meriolins, a new class of cyclin-dependent kinase inhibitors, on malignant glioma proliferation and neo-angiogenesis

Jarry, M., Lecointre, C., Malleval, C., Desrues, L., Schouft, M., Joncour, V. L., Liger, F., Lyvinec, G., Joseph, B., Loaëc, N., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou102 · Cited by 31 · see citing works

Direct Association of Sprouty-related Protein with an EVH1 Domain (SPRED) 1 or SPRED2 with DYRK1A Modifies Substrate/Kinase Interactions

Li, D., Jackson, R. A., Yusoff, P., & Guy, G. R. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.148445 · Cited by 30 · see citing works

DYRK1A Negatively Regulates CDK5-SOX2 Pathway and Self-Renewal of Glioblastoma Stem Cells

Chen, B., McCuaig-Walton, D., Tan, S. J. X., Montgomery, A. P., Day, B. W., Kassiou, M., Munoz, L., & Recasens, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084011 · Cited by 30 · see citing works

DYRK1A is required for maintenance of cancer stemness, contributing to tumorigenic potential in oral/oropharyngeal squamous cell carcinoma

Martin, C. E., Nguyen, A., Kang, M., et al. (2021) · Experimental Cell Research · doi:10.1016/j.yexcr.2021.112656 · Cited by 28 · see citing works

Mirk kinase inhibition blocks the in vivo growth of pancreatic cancer cells

Deng, X., & Friedman, E. (2014) · Genes & Cancer · doi:10.18632/genesandcancer.29 · Cited by 27 · see citing works

In-vitro antiproliferative activities and kinase inhibitory potencies of meridianin derivatives

Rossignol, E., Débiton, E., Fabbro, D., et al. (2008) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32830ce4d8 · Cited by 27 · see citing works

DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors

Li, Y., Zhou, D., Xu, S., et al. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2019.0380 · Cited by 26 · see citing works

Silmitasertib (CX-4945) in combination with gemcitabine and cisplatin as first-line treatment for patients with locally advanced or metastatic cholangiocarcinoma: A phase Ib/II study.

Borad, M. J., Bai, L., Chen, M., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.3_suppl.312 · Cited by 26 · see citing works

K63-linked ubiquitination of DYRK1A by TRAF2 alleviates Sprouty 2-mediated degradation of EGFR

Zhang, P., Zhang, Z., Fu, Y., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03887-2 · Cited by 26 · see citing works

Banisteriopsis caapi , a Forgotten Potential Therapy for Parkinson's Disease?

Djamshidian, A., Bernschneider‐Reif, S., Poewe, W. H., & Lees, A. J. (2015) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12242 · Cited by 25 · see citing works

Vascular defects of DYRK1A knockouts are ameliorated by modulating calcium signaling in zebrafish

Cho, H.-J., Lee, J.-G., Kim, S., Kim, S., Huh, Y. H., Kim, H., Lee, K., Yu, K., & Lee, J.-S. (2019) · Disease Models & Mechanisms · doi:10.1242/dmm.037044 · Cited by 25 · see citing works

Licocoumarone induces BxPC-3 pancreatic adenocarcinoma cell death by inhibiting DYRK1A

Zhao, C., Wang, D., Gao, Z., et al. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.108913 · Cited by 23 · see citing works

Discovery and Characterization of Selective and Ligand-Efficient DYRK Inhibitors

Henderson, S. H., Sorrell, F. J., Bennett, J. M., Fedorov, O., Hanley, M. T., Godoi, P. H., de Sousa, R. R. R., Robinson, S. W., Ashall-Kelly, A., Navratilova, I. H., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01115 · Cited by 23 · see citing works

Mining Public Domain Data to Develop Selective DYRK1A Inhibitors

Henderson, S. H., Sorrell, F. J., Bennett, J. M., Hanley, M. T., Robinson, S. W., Navratilova, I. H., Elkins, J. M., & Ward, S. E. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00279 · Cited by 21 · see citing works

Meridianin C inhibits the growth of YD‐10B human tongue cancer cells through macropinocytosis and the down‐regulation of Dickkopf‐related protein‐3

Park, N., Park, Y., Ramalingam, M., Yadav, A. K., Cho, H., Hong, V. S., More, K. N., Bae, J., Bishop‐Bailey, D., Kano, J., et al. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13854 · Cited by 20 · see citing works

DCAF7/WDR68 is required for normal levels of DYRK1A and DYRK1B

Yousefelahiyeh, M., Xu, J., Alvarado, E., Yang, Y., Salven, D. S., & Nissen, R. M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0207779 · Cited by 19 · see citing works

E3 Ligase SCFβTrCP-induced DYRK1A Protein Degradation Is Essential for Cell Cycle Progression in HEK293 Cells*

Liu, Q., Tang, Y., Chen, L., Liu, N., Lang, F., Liu, H., Wang, P., & Sun, X.-L. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.717553 · Cited by 18 · see citing works

Dual-specificity tyrosine-phosphorylation regulated kinase 1A Gene Transcription is regulated by Myocyte Enhancer Factor 2D

Wang, P., Wang, L., Chen, L., & Sun, X. (2017) · Scientific Reports · doi:10.1038/s41598-017-07655-1 · Cited by 18 · see citing works

Casein Kinase 2 Inhibitor, CX-4945, as a Potential Targeted Anticancer Agent in Gastric Cancer

Kim, H. M., Jeong, I., Kim, H. J., et al. (2018) · Anticancer Research · doi:10.21873/anticanres.12970 · Cited by 18 · see citing works

Green tea extract for prevention of prostate cancer progression in patients on active surveillance

Kumar, N. B., Dickinson, S. I., Schell, M. J., Manley, B. J., Poch, M. A., & Pow‐Sang, J. M. (2018) · Oncotarget · doi:10.18632/oncotarget.26519 · Cited by 15 · see citing works

Small Molecule Inhibitors of DYRK1A Identified by Computational and Experimental Approaches

Yoon, H. R., Balupuri, A., Choi, K.-E., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186826 · Cited by 14 · see citing works

How to Separate Kinase Inhibition from Undesired Monoamine Oxidase A Inhibition—The Development of the DYRK1A Inhibitor AnnH75 from the Alkaloid Harmine

Wurzlbauer, A., Rüben, K., Gürdal, E. E., Chaikuad, A., Knapp, S., Sippl, W., Becker, W. B., & Bracher, F. (2020) · Molecules · doi:10.3390/molecules25245962 · Cited by 13 · see citing works

DYRK1A phosphorylates MEF2D and decreases its transcriptional activity

Wang, P., Zhao, J., & Sun, X. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16505 · Cited by 13 · see citing works

Visualization and quantification of dynamic STAT3 homodimerization in living cells using homoFluoppi

Okada, Y., Watanabe, T., Shoji, T., Taguchi, K., Ogo, N., & Asai, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-20234-2 · Cited by 11 · see citing works

Biological Characterization of 8-Cyclopropyl-2-(pyridin-3-yl)thiazolo[5,4-f]quinazolin-9(8H)-one, a Promising Inhibitor of DYRK1A

Fruit, C., Couly, F., Bhansali, R. S., et al. (2019) · Pharmaceuticals · doi:10.3390/ph12040185 · Cited by 11 · see citing works

Development of Kinase Inhibitors via Metal-Catalyzed C–H Arylation of 8-Alkyl-thiazolo[5,4-f]-quinazolin-9-ones Designed by Fragment-Growing Studies

Couly, F., Harari, M., Dubouilh‐Benard, C., Bailly, L., Petit, É., Diharce, J., Bonnet, P., Meijer, L., Fruit, C., & Besson, T. (2018) · Molecules · doi:10.3390/molecules23092181 · Cited by 8 · see citing works

A Novel DYRK1A (Dual Specificity Tyrosine Phosphorylation-Regulated Kinase 1A) Inhibitor for the Treatment of Alzheimer’s Disease: Effect on Tau and Amyloid Pathologies in Vitro.

Coutadeur, S., Benyamine, H., Delalonde, L., et al. (2015) · HAL (Le Centre pour la Communication Scientifique Directe) · Cited by 8 · see citing works

DYRK1A regulates the recruitment of 53BP1 to the sites of DNA damage in part through interaction with RNF169Preprint

Menon, V., Ananthapadmanabhan, V., Swanson, S. K., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/327510 · Cited by 5 · see citing works

The nuclear interactome of DYRK1A reveals a functional role in DNA damage repairPreprint

Guard, S. E., Poss, Z. C., Ebmeier, C. C., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/432757 · Cited by 5 · see citing works

Modulation of RNA Splicing Enhances Response to BCL2 Inhibition in Acute Myeloid Leukemia

Wang, E., Pineda, J. M. B., Bourcier, J., et al. (2021) · Blood · doi:10.1182/blood-2021-146373 · Cited by 3 · see citing works

DYRK1A Is Required to Alleviate Replication Stress in KMT2A-Rearranged Acute Lymphoblastic Leukemia

Hurtz, C., Carroll, M. P., Tasian, S. K., et al. (2020) · Blood · doi:10.1182/blood-2020-141258 · Cited by 2 · see citing works

The Omnipresence of DYRK1A in Human Diseases

Deboever, E., Fistrovich, A., Hulme, C., & Dunckley, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169355 · Cited by 77 · see citing works

A genome-wide screen reveals that Dyrk1A kinase promotes nucleotide excision repair by preventing aberrant overexpression of cyclin D1 and p21

Bélanger, F., Roussel, C., Sawchyn, C., St-Hilaire, E., Gezzar-Dandashi, S., Kimenyi Ishimwe, A. B., Mallette, F. A., Wurtele, H., & Drobetsky, E. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104900 · Cited by 9 · see citing works

Discovery of DB18, a potent inhibitor of CLK kinases with a high selectivity against DYRK1A kinase

Brahmaiah, D., Bhavani, A. K. D., Aparna, P., Kumar, N. S., Solhi, H., Guével, R. L., Baratte, B., Ruchaud, S., Bach, S., Jadav, S. S., et al. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115962 · Cited by 21 · see citing works

Silmitasertib (CX-4945), a Clinically Used CK2-Kinase Inhibitor with Additional Effects on GSK3β and DYRK1A Kinases: A Structural Perspective

Grygier, P., Pustelny, K., Nowak, J., Golik, P., Popowicz, G. M., Plettenburg, O., Dubin, G., Menezes, F., & Czarna, A. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01887 · Cited by 58 · see citing works

Conception of DYRK1A kinase inhibitors via metal-catalyzed C–H arylation, inspired by fragment-growing studies

Besson, T., Couly, F., Diharce, J., et al. (2018) · International Electronic Conference on Medicinal Chemistry (ECMC) · doi:10.3390/ecmc-4-05580 · Cited by 1 · see citing works

Structure Activity Relationship Studies around DB18, a Potent and Selective Inhibitor of CLK Kinases

Brahmaiah, D., Bhavani, A. K. D., Aparna, P., et al. (2022) · Molecules · doi:10.3390/molecules27196149 · Cited by 5 · see citing works

Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk)

Rosenthal, A. S., Tanega, C., Shen, M., Mott, B. T., Bougie, J. M., Nguyễn, Ð.-T., Misteli, T., Auld, D. S., Maloney, D. J., & Thomas, C. J. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.02.114 · Cited by 73 · see citing works